BofA Securities Upgrades Fate Therapeutics (FATE) to Neutral, 'Following initial autoimmune clinical data presented at ACR Convergence'
Tweet Send to a Friend
(Updated - November 18, 2024 3:49 PM EST)
BofA Securities analyst Tazeen Ahmad upgraded Fate Therapeutics (NASDAQ: FATE) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
BofA Securities analyst Tazeen Ahmad upgraded Fate Therapeutics (NASDAQ: FATE) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
